RU96101808A - AGENT FOR PROCESSING SENSITIVE SKIN, COMPOSITION ON ITS BASIS AND METHOD FOR PROCESSING SKIN - Google Patents

AGENT FOR PROCESSING SENSITIVE SKIN, COMPOSITION ON ITS BASIS AND METHOD FOR PROCESSING SKIN

Info

Publication number
RU96101808A
RU96101808A RU96101808/14A RU96101808A RU96101808A RU 96101808 A RU96101808 A RU 96101808A RU 96101808/14 A RU96101808/14 A RU 96101808/14A RU 96101808 A RU96101808 A RU 96101808A RU 96101808 A RU96101808 A RU 96101808A
Authority
RU
Russia
Prior art keywords
composition
agents
skin
cgrp antagonist
cgrp
Prior art date
Application number
RU96101808/14A
Other languages
Russian (ru)
Other versions
RU2180854C2 (en
Inventor
Бретон Лионель
Де Ляшарьер Оливье
Original Assignee
Л'Ореаль
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from FR9500900A external-priority patent/FR2729855A1/en
Application filed by Л'Ореаль filed Critical Л'Ореаль
Publication of RU96101808A publication Critical patent/RU96101808A/en
Application granted granted Critical
Publication of RU2180854C2 publication Critical patent/RU2180854C2/en

Links

Claims (19)

1. Применение по меньшей мере одного антагониста CGRP в композиции, содержащей косметически, дерматологически или фармакологически пригодную среду, в качестве агента для обработки чувствительной кожи.1. The use of at least one CGRP antagonist in a composition containing a cosmetically, dermatologically or pharmacologically suitable medium as an agent for treating sensitive skin. 2. Применение по п.1, при котором антагонистом CGRP является молекула, выбранная из CGRP 8 - 37, и антитела анти-CGRP. 2. The use according to claim 1, wherein the CGRP antagonist is a molecule selected from CGRP 8 to 37, and anti-CGRP antibodies. 3. Применение по любому из вышеуказанных пунктов, при котором антагонист CGRP используют в количестве, составляющем от 0,000001 до 10 вес.% по отношению к общему весу композиции. 3. The use according to any one of the above paragraphs, wherein the CGRP antagonist is used in an amount of from 0.000001 to 10 wt.% With respect to the total weight of the composition. 4. Применение по любому из вышеуказанных пунктов, при котором антагонист CGRP используют в количестве, составляющем от 0,0001 до 5 вес.% по отношению к общему весу композиции. 4. The use according to any one of the above paragraphs, wherein the CGRP antagonist is used in an amount of from 0.0001 to 5 wt.% With respect to the total weight of the composition. 5. Применение по любому из вышеуказанных пунктов, согласно которому косметически, фармакологически или дерматологически пригодная среда представляет собой водный раствор, масляный раствор или водно-спиртовой раствор, эмульсию вода-в-масле, эмульсию масло-в-воде, микроэмульсию, водный гель, безводный гель, сыворотку, дисперсию пузырьков, микрокапсул или микрочастиц. 5. The use according to any one of the above paragraphs, according to which the cosmetically, pharmacologically or dermatologically suitable medium is an aqueous solution, an oil solution or an aqueous-alcoholic solution, a water-in-oil emulsion, an oil-in-water emulsion, a microemulsion, an aqueous gel, anhydrous gel, serum, dispersion of vesicles, microcapsules or microparticles. 6. Применение по любому из вышеуказанных пунктов, при котором композиция содержит по меньшей мере один агент, выбранный среди антибактерицидных агентов, противопаразитарных агентов, противогрибковых агентов, противовоспалительных агентов, противозудных агентов, анестезирующих агентов, противовирусных агентов, кератолитических агентов, агентов, препятствующих образованию свободных радикалов, противосеборрейных агентов, агентов, противодействующих образованию перхоти, агентов противоугревого действия и/или агентов, модулирующих дифференциацию, и/или разрастание, и/или пигментацию кожи. 6. The use according to any one of the above paragraphs, wherein the composition comprises at least one agent selected among antibacterial agents, antiparasitic agents, antifungal agents, anti-inflammatory agents, antipruritic agents, anesthetics, antiviral agents, keratolytic agents, anti-free agents radicals, anti-seborrheic agents, anti-dandruff agents, anti-acne agents and / or differential modulating agents skination and / or overgrowth and / or skin pigmentation. 7. Применение по предшествующему пункту, при котором агент представляет собой хлоргидрат лидокаина, какое-либо антипаразитивное вещество или противовоспалительное вещество нестероидного типа. 7. The use according to the preceding paragraph, wherein the agent is lidocaine hydrochloride, an anti-parasitic substance or non-steroidal anti-inflammatory substance. 8. Применение по п. 1 в композициях топического назначения для профилактики и/или противодействия кожным раздражениям, и/или лишаям, и/или эритем, и/или дизестезий, или зуду кожи и/или слизистых оболочек. 8. The use according to claim 1 in topical compositions for the prophylaxis and / or counteraction of skin irritations, and / or lichen, and / or erythema, and / or dysesthesia, or itching of the skin and / or mucous membranes. 9. Способ косметической обработки, отличающийся тем, что наносят на кожу, на кожу волосистой части головы и/или на слизистые оболочки композицию, содержащую по меньшей мере один антагонист CGRP в косметически пригодной среде. 9. A method of cosmetic treatment, characterized in that it is applied to the skin, on the skin of the scalp and / or on the mucous membranes of a composition containing at least one CGRP antagonist in a cosmetically suitable medium. 10. Способ по п. 9, отличающийся тем, что антагонист CGRP выбирают из CGRP 8 - 37 и антител анти-CGRP. 10. The method according to p. 9, characterized in that the CGRP antagonist is selected from CGRP 8 to 37 and anti-CGRP antibodies. 11. Способ по п.9 или 10, отличающийся тем, что антагонист CGRP используют в количестве, составляющем от 0,000001 до 10 вес.% по отношению к общему весу композиции. 11. The method according to claim 9 or 10, characterized in that the CGRP antagonist is used in an amount of from 0.000001 to 10 wt.% In relation to the total weight of the composition. 12. Способ по любому из пп.9 - 11, отличающийся тем, что антагонист CGRP используют в количестве, составляющем от 0,00001 до 5 вес.% по отношению к общему весу композиции. 12. The method according to any one of claims 9 to 11, characterized in that the CGRP antagonist is used in an amount of from 0.00001 to 5 wt.% With respect to the total weight of the composition. 13. Композиция, содержащая косметически, фармакологически или дерматологически пригодную среду и, при необходимости, по меньшей мере одно вещество с побочным раздражающим действием, отличающаяся тем, что она содержит, кроме того, по меньшей мере один антагонист CGRP. 13. A composition comprising a cosmetically, pharmacologically or dermatologically suitable medium and, if necessary, at least one substance with a side irritant effect, characterized in that it also contains at least one CGRP antagonist. 14. Косметическая композиция по п.13, отличающаяся тем, что антагонист CGRP выбран среди органических или минеральных молекул. 14. The cosmetic composition according to item 13, wherein the CGRP antagonist is selected among organic or mineral molecules. 15. Косметическая композиция по п.13 или 14, отличающаяся тем, что антагонист CGRP использован в количестве, составляющем от 0,000001 до 10 вес.% по отношению к общему весу композиции. 15. The cosmetic composition according to item 13 or 14, characterized in that the CGRP antagonist is used in an amount of from 0.000001 to 10 wt.% In relation to the total weight of the composition. 16. Косметическая композиция по любому из пп.13 - 15, отличающаяся тем, что антагонист CGRP использован в количестве, составляющем от 0,0001 до 5 вес.% по отношению к общему весу композиции. 16. The cosmetic composition according to any one of paragraphs.13 to 15, characterized in that the CGRP antagonist is used in an amount of from 0.0001 to 5 wt.% In relation to the total weight of the composition. 17. Косметическая композиция по любому из пп.13 - 16, отличающаяся тем, что вещество с побочным раздражающим действием выбрано среди альфа-оксикислот, бета-оксикислот, альфа-кетокислот, бета-кетокислот, ретиноидов, антралинов, антраноидов, перекисей, миноксидила, солей лития, антиметаболитов, витамина D и его производных, дипигментантов, растворителей, отдушек, консервантов, поверхностно-активных веществ, спиртовых растворов. 17. The cosmetic composition according to any one of paragraphs.13 to 16, characterized in that the substance with a side irritating effect is selected among alpha hydroxy acids, beta hydroxy acids, alpha keto acids, beta keto acids, retinoids, anthralins, anthranoids, peroxides, minoxidil, lithium salts, antimetabolites, vitamin D and its derivatives, dipigmentants, solvents, fragrances, preservatives, surfactants, alcohol solutions. 18. Косметическая композиция по любому из пп.13 - 17, отличающаяся тем, что она содержит, кроме того, по меньшей мере один агент, выбранный среди противобактерицидных агентов, противопаразитарных агентов, противогрибковых агентов, противовоспалительных агентов, противозудных агентов, анестезирующих агентов, антивирусных агентов, кератолитических агентов, агентов, препятствующих образованию свободных радикалов, противосеборрейных агентов, агентов, препятствующих образованию перхоти, агентов противоугревого действия и/или агентов, вызывающих дифференциацию, и/или пролиферацию, и/или пигментацию кожи. 18. The cosmetic composition according to any one of paragraphs.13 to 17, characterized in that it contains, at the same time, at least one agent selected from antibacterial agents, antiparasitic agents, antifungal agents, anti-inflammatory agents, antipruritic agents, anesthetizing agents, antiviral agents, keratolytic agents, anti-free radical agents, anti-seborrheic agents, anti-dandruff agents, anti-acne agents and / or agents causing differentiation and / or proliferation and / or skin pigmentation. 19. Косметическая композиция по любому из пп.13 - 18, отличающаяся тем, что она представляет собой композицию для очистки, композицию для защиты, композицию для обработки, композицию для образования искусственного загара или композицию для ухода за лицом, за руками, за ногами, за складками тела или за телом, вещество для макияжа, молочко для удаления макияжа, продукт для обработки кожи после воздействия солнечных лучей, композицию для ванны, дезодорирующую композицию, композицию для обработки морщин, угрей, или гиперсеборрейной кожи, или себоррейных дермитов, вещество, используемое после бритья, крем для удаления волос, композицию, защищающую от укусов насекомых, композицию, обладающую противоболевым эффектом, композицию для ухода или композицию, обеспечивающую капиллярную обработку, шампуни, средства для укладки волос, средства для завивки волос, средства для окраски волос, средства для моделирования причесок, композиции, противодействующие выпадению волос, составы для обработки полости рта и зубов. 19. Cosmetic composition according to any one of paragraphs.13 to 18, characterized in that it is a composition for cleaning, composition for protection, composition for processing, composition for the formation of artificial tanning or composition for the care of the face, hands, feet, for wrinkles of the body or behind the body, makeup material, makeup remover, product for treating the skin after exposure to the sun, bath composition, deodorizing composition, composition for treating wrinkles, blackheads or hyperseborrhoeic skin, or seborrhea some dermatitis, a substance used after shaving, a cream for removing hair, a composition that protects against insect bites, a composition that has an analgesic effect, a skin care composition or a composition that provides capillary treatment, shampoos, hair styling products, hair curlers, products for hair coloring, tools for modeling hairstyles, compositions that counteract hair loss, compositions for treating the oral cavity and teeth.
RU96101808/14A 1995-01-26 1996-01-25 Agent for treatment of sensitive skin, composition based on thereof and method of skin treatment RU2180854C2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9500900 1995-01-26
FR9500900A FR2729855A1 (en) 1995-01-26 1995-01-26 USE OF A CGRP ANTAGONIST IN A COSMETIC, PHARMACEUTICAL OR DERMATOLOGICAL COMPOSITION AND COMPOSITION OBTAINED

Publications (2)

Publication Number Publication Date
RU96101808A true RU96101808A (en) 1998-05-10
RU2180854C2 RU2180854C2 (en) 2002-03-27

Family

ID=9475528

Family Applications (1)

Application Number Title Priority Date Filing Date
RU96101808/14A RU2180854C2 (en) 1995-01-26 1996-01-25 Agent for treatment of sensitive skin, composition based on thereof and method of skin treatment

Country Status (14)

Country Link
US (1) US6019967A (en)
EP (1) EP0723774B1 (en)
JP (1) JP3043608B2 (en)
AR (1) AR002023A1 (en)
AT (1) ATE197896T1 (en)
BR (1) BR9600487A (en)
CA (1) CA2167980C (en)
DE (1) DE69611106T2 (en)
DK (1) DK0723774T3 (en)
ES (1) ES2154388T3 (en)
FR (1) FR2729855A1 (en)
HU (1) HUP9600162A3 (en)
PL (1) PL184701B1 (en)
RU (1) RU2180854C2 (en)

Families Citing this family (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6416760B2 (en) * 1995-01-26 2002-07-09 Societe L'oreal Therapeutic/cosmetic compositions comprising CGRP antagonists for treating sensitive human skin
MX9710479A (en) * 1995-09-07 1998-03-31 Oreal Extract of iridaceae and compositions containing such extract.
JP3483893B2 (en) * 1996-09-10 2004-01-06 ドクトル カルル トーマエ ゲゼルシャフト ミット ベシュレンクテル ハフツング Modified amino acids, drugs containing these compounds and methods for their preparation
US6313097B1 (en) 1999-03-02 2001-11-06 Boehringer Ingelheim Pharma Kg Antagonists of calcitonin gene-related peptide
US7393548B2 (en) * 1999-03-22 2008-07-01 J.P. M.E.D. Ltd. Nano oil in glycerin emulsion
DE19952147A1 (en) 1999-10-29 2001-05-03 Boehringer Ingelheim Pharma New cyclopropanes, pharmaceutical compositions containing these compounds and process for their preparation
DE19958121A1 (en) * 1999-12-02 2001-06-28 Max Planck Gesellschaft Tyrosine and tryptophan-containing peptides as antioxidants
US8512718B2 (en) 2000-07-03 2013-08-20 Foamix Ltd. Pharmaceutical composition for topical application
WO2002026191A2 (en) * 2000-09-28 2002-04-04 Nanocyte Inc. Methods, compositions and devices utilizing stinging cells/capsules for delivering a therapeutic or a cosmetic agent into a tissue
US7632522B2 (en) 2000-09-28 2009-12-15 Nanocyte Inc. Use of stinging cells/capsules for the delivery of active agents to keratinous substances
US6632420B1 (en) 2000-09-28 2003-10-14 The Gillette Company Personal care product
IL164191A0 (en) * 2002-03-26 2005-12-18 Nanocyte Inc Stinging cells expressing an exogenous polynucleotide encoding a therapeutic, diagnostic or a cosme tic agent and methods compositions and devices utilizing such stinging cells or capsules derived therefrom for delivering the therapeutic, diagnostic or cosmetic agent into a tissue nanocyte inc.
DK1556020T3 (en) * 2002-08-12 2009-06-22 Birkir Sveinsson Use of CGRP antagonist compounds for the treatment of psoriasis
IL152486A0 (en) 2002-10-25 2003-05-29 Meir Eini Alcohol-free cosmetic and pharmaceutical foam carrier
AU2003279493B2 (en) 2002-10-25 2009-08-20 Foamix Pharmaceuticals Ltd. Cosmetic and pharmaceutical foam
US20050186142A1 (en) * 2002-10-25 2005-08-25 Foamix Ltd. Kit and composition of imidazole with enhanced bioavailability
US20080138296A1 (en) 2002-10-25 2008-06-12 Foamix Ltd. Foam prepared from nanoemulsions and uses
US8900554B2 (en) 2002-10-25 2014-12-02 Foamix Pharmaceuticals Ltd. Foamable composition and uses thereof
US20050271596A1 (en) * 2002-10-25 2005-12-08 Foamix Ltd. Vasoactive kit and composition and uses thereof
US20060018937A1 (en) * 2002-10-25 2006-01-26 Foamix Ltd. Steroid kit and foamable composition and uses thereof
US20070292355A1 (en) * 2002-10-25 2007-12-20 Foamix Ltd. Anti-infection augmentation foamable compositions and kit and uses thereof
US9668972B2 (en) 2002-10-25 2017-06-06 Foamix Pharmaceuticals Ltd. Nonsteroidal immunomodulating kit and composition and uses thereof
US20060193789A1 (en) * 2002-10-25 2006-08-31 Foamix Ltd. Film forming foamable composition
US8119109B2 (en) * 2002-10-25 2012-02-21 Foamix Ltd. Foamable compositions, kits and methods for hyperhidrosis
US7704518B2 (en) * 2003-08-04 2010-04-27 Foamix, Ltd. Foamable vehicle and pharmaceutical compositions thereof
US8119150B2 (en) 2002-10-25 2012-02-21 Foamix Ltd. Non-flammable insecticide composition and uses thereof
US9265725B2 (en) * 2002-10-25 2016-02-23 Foamix Pharmaceuticals Ltd. Dicarboxylic acid foamable vehicle and pharmaceutical compositions thereof
US20080317679A1 (en) * 2002-10-25 2008-12-25 Foamix Ltd. Foamable compositions and kits comprising one or more of a channel agent, a cholinergic agent, a nitric oxide donor, and related agents and their uses
US9211259B2 (en) 2002-11-29 2015-12-15 Foamix Pharmaceuticals Ltd. Antibiotic kit and composition and uses thereof
US10117812B2 (en) 2002-10-25 2018-11-06 Foamix Pharmaceuticals Ltd. Foamable composition combining a polar solvent and a hydrophobic carrier
US7820145B2 (en) * 2003-08-04 2010-10-26 Foamix Ltd. Oleaginous pharmaceutical and cosmetic foam
US8486376B2 (en) * 2002-10-25 2013-07-16 Foamix Ltd. Moisturizing foam containing lanolin
US7700076B2 (en) 2002-10-25 2010-04-20 Foamix, Ltd. Penetrating pharmaceutical foam
US20040120915A1 (en) * 2002-12-19 2004-06-24 Kaiyuan Yang Multifunctional compositions for surface applications
EP1452167A1 (en) * 2003-02-28 2004-09-01 Cognis France S.A. Cosmetic, pharmaceutical and/or dermatological composition comprising an extract of Eperua falcata
US7575739B2 (en) 2003-04-28 2009-08-18 Foamix Ltd. Foamable iodine composition
US8486374B2 (en) * 2003-08-04 2013-07-16 Foamix Ltd. Hydrophilic, non-aqueous pharmaceutical carriers and compositions and uses
US8795693B2 (en) 2003-08-04 2014-08-05 Foamix Ltd. Compositions with modulating agents
US8834862B2 (en) * 2005-04-19 2014-09-16 Nanocyte Inc. Methods, compositions and devices utilizing stinging cells/capsules for conditioning a tissue prior to delivery of an active agent
JP2008540508A (en) * 2005-05-09 2008-11-20 フォーミックス エルティーディー. Foaming vehicle and pharmaceutical composition thereof
US20080152596A1 (en) * 2005-07-19 2008-06-26 Foamix Ltd. Polypropylene glycol foamable vehicle and pharmaceutical compositions thereof
US8168592B2 (en) * 2005-10-21 2012-05-01 Amgen Inc. CGRP peptide antagonists and conjugates
CN102525829B (en) * 2006-03-07 2014-08-06 埃莱文斯可更新科学公司 Compositions comprising metathesized unsaturated polyol esters
CN101500608A (en) 2006-06-08 2009-08-05 中外制药株式会社 Preventive or remedy for inflammatory disease
JP2010502690A (en) * 2006-09-08 2010-01-28 フォーミックス エルティーディー. Colored or colorable foamable composition
US20080206155A1 (en) * 2006-11-14 2008-08-28 Foamix Ltd. Stable non-alcoholic foamable pharmaceutical emulsion compositions with an unctuous emollient and their uses
US20080260655A1 (en) * 2006-11-14 2008-10-23 Dov Tamarkin Substantially non-aqueous foamable petrolatum based pharmaceutical and cosmetic compositions and their uses
EP1986473B1 (en) * 2007-04-03 2017-01-25 Tsinghua University Organic electroluminescent device
US8636982B2 (en) 2007-08-07 2014-01-28 Foamix Ltd. Wax foamable vehicle and pharmaceutical compositions thereof
US20090130029A1 (en) * 2007-11-21 2009-05-21 Foamix Ltd. Glycerol ethers vehicle and pharmaceutical compositions thereof
WO2009069006A2 (en) 2007-11-30 2009-06-04 Foamix Ltd. Foam containing benzoyl peroxide
ES2834741T3 (en) 2007-12-05 2021-06-18 Chugai Pharmaceutical Co Ltd Anti-NR10 antibody and its use
CA2708065C (en) * 2007-12-05 2015-02-24 Chugai Seiyaku Kabushiki Kaisha Therapeutic agent for pruritus
WO2010041141A2 (en) 2008-10-07 2010-04-15 Foamix Ltd. Oil-based foamable carriers and formulations
WO2009072007A2 (en) 2007-12-07 2009-06-11 Foamix Ltd. Carriers, formulations, methods for formulating unstable active agents for external application and uses thereof
WO2009090558A2 (en) * 2008-01-14 2009-07-23 Foamix Ltd. Poloxamer foamable pharmaceutical compositions with active agents and/or therapeutic cells and uses
US20120087872A1 (en) 2009-04-28 2012-04-12 Foamix Ltd. Foamable Vehicles and Pharmaceutical Compositions Comprising Aprotic Polar Solvents and Uses Thereof
CA2769625C (en) 2009-07-29 2017-04-11 Foamix Ltd. Non surfactant hydro-alcoholic foamable compositions, breakable foams and their uses
WO2011013008A2 (en) 2009-07-29 2011-02-03 Foamix Ltd. Non surface active agent non polymeric agent hydro-alcoholic foamable compositions, breakable foams and their uses
US9849142B2 (en) 2009-10-02 2017-12-26 Foamix Pharmaceuticals Ltd. Methods for accelerated return of skin integrity and for the treatment of impetigo
CN102686205A (en) 2009-10-02 2012-09-19 弗艾米克斯有限公司 Topical tetracycline compositions
FR3001391B1 (en) * 2013-01-29 2017-07-07 Oreal USE OF ELIDITE IRIDACEE VEGETABLE CELLS IN THE TREATMENT OF SENSITIVE SKIN
BR112017022101A2 (en) 2015-04-14 2018-07-31 Chugai Seiyaku Kabushiki Kaisha pharmaceutical composition for prevention and / or treatment of atopic dermatitis containing il-31 antagonist as an active ingredient
MX2017011630A (en) 2016-09-08 2018-09-25 Foamix Pharmaceuticals Ltd Compositions and methods for treating rosacea and acne.
US11433119B2 (en) * 2016-11-18 2022-09-06 Nepsone Ehf Methods of treating inflammatory skin disorders
GB2576208B (en) * 2018-08-10 2023-05-17 Exit Surf Street Summit Ltd Hanger for holding watersport garments
BR112022006590A2 (en) 2019-11-20 2022-06-28 Chugai Pharmaceutical Co Ltd PREPARATION CONTAINING ANTIBODIES
RU2732295C1 (en) * 2020-01-10 2020-09-15 Федеральное государственное бюджетное образовательное учреждение высшего образования "Амурская государственная медицинская академия" Министерства здравоохранения Российской Федерации Preparation for strengthening and stimulating hair growth and method of using it
CN116456981A (en) * 2020-11-19 2023-07-18 辉瑞爱尔兰制药公司 Compositions for improved GRP inhibitor delivery

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2524310A2 (en) * 1982-04-01 1983-10-07 Olivier Georges COMPOSITIONS FOR COMBATTING MEASURES AND DISADVANTAGES OF PERSPIRATION
US5013545A (en) * 1987-12-09 1991-05-07 Thames Pharmacal Co., Inc. Aqueous gels containing topical medicaments
SE9201425D0 (en) * 1992-05-06 1992-05-06 Kabi Pharmacia Ab METHOD AND MEANS FOR PREVENTING CONSTRICTION OF THE PUPIL IN THE EYE
JPH08501553A (en) * 1992-09-14 1996-02-20 スミス・ウォルター・ピー Skin conditioning composition, its application and manufacture
US5420106A (en) * 1994-03-22 1995-05-30 Bristol-Myers Squibb Company Method and composition having enhanced alpha-hydroxy acid skin permeation and retention
US5543148A (en) * 1994-07-12 1996-08-06 Combe, Incorporated Stick delivery system for topical application of a treatment agent

Similar Documents

Publication Publication Date Title
RU96101808A (en) AGENT FOR PROCESSING SENSITIVE SKIN, COMPOSITION ON ITS BASIS AND METHOD FOR PROCESSING SKIN
RU2180854C2 (en) Agent for treatment of sensitive skin, composition based on thereof and method of skin treatment
ES2218537T3 (en) COSMETIC, PHARMACEUTICAL OR DERMATOLOGICAL COMPOSITION CONTAINING A TNF-ALFA ANTAGONIST.
JP2975431B2 (en) NO-synthase inhibitor
JPH11501941A (en) Topical composition containing capsazepine
JP3110050B2 (en) Use of at least one NO synthase inhibitor in the treatment of sensitive skin
ES2246493T3 (en) USE OF MANGANESE, ITRIO OR CERTAIN LANTANID SALTS FOR THE PREPARATION OF A COSMETIC, DERMATOLOGICAL OR PHARMACEUTICAL COMPOSITION INTENDED ON EVERYTHING TO TREAT SENSITIVE SKIN.
JP2783520B2 (en) Method of using substance P antagonists in cosmetic compositions and compositions thereof
US6248763B1 (en) Composition for treating skin conditions
US20040102358A1 (en) Composition for treating skin conditions
JP2002293718A (en) Use of fiber as antiirritant in cosmetic or dermatological composition
PT722736E (en) COMPOSITION TOPIC CONTAINING AN ANTAGONISTA OF SUBSTANCE P
JP2922157B2 (en) Use of Bradykinin Antagonists in Cosmetic, Pharmaceutical, or Dermatological Compositions and Compositions Thereof
JP3712328B2 (en) Use of excitatory amino acid inhibitors and cosmetic compositions containing the same
JP3636473B2 (en) Use of at least one beta-adrenergic agonist as a substance P antagonist
JP2002363058A (en) Use of composition containing at least one kind of chelating agent for increasing tolerance limit of sensitive skin or nonresistive skin
JPH10511360A (en) Formulations and methods for reducing skin irritation
JP3025466B2 (en) Uses of oxazolidinone derivatives in cosmetics, etc.
US5714155A (en) Ethylenediamine derivative in a cosmetic or dermatological composition, and composition containing in particular a product having an irritant side effect
JP2001511782A (en) Use of serotonin antagonists or agonists specific for the 5HT lower 2 and 5HT lower 1D receptors, respectively, in cosmetic or dermatological compositions for sensitive skin
JPH01193205A (en) Cosmetics composition
JP2000290252A (en) New compound of benzylaminodiacetamide family, and composition, production and use of the compound
JPH0881368A (en) External therapeutic agent for chromatosis
RU2176511C1 (en) Agent for prophylaxis of acne disease and method of its preparing
JPS62192311A (en) Hair tonic cosmetic